The European Patent Office (EPO) has published patent application EP4175650A1, titled 'MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE SAME AND USES THEREOF'. The publication date is March 11, 2026, and the applicant is Immunocell Therapeutics, Inc. This publication relates to novel binding molecules and their applications, potentially impacting the development of new therapies.

This is a patent publication, not a regulatory rule or guidance with direct compliance obligations for regulated entities. Compliance officers should note this publication as it may indicate future product development or competitive landscape shifts within the pharmaceutical and biotechnology sectors. No immediate actions or deadlines are imposed by this patent publication.